Literature DB >> 15893168

Multiple overlapping drug-eluting stents to treat diffuse disease of the left anterior descending coronary artery.

Eleftheria Tsagalou1, Alaide Chieffo, Ioannis Iakovou, Lei Ge, Giuseppe M Sangiorgi, Nicola Corvaja, Flavio Airoldi, Matteo Montorfano, Iassen Michev, Antonio Colombo.   

Abstract

OBJECTIVES: We sought to determine the safety and efficacy of using multiple overlapping drug-eluting stents (DES) in patients with diffuse left anterior descending coronary artery (LAD) disease.
BACKGROUND: Diffuse LAD disease represents a therapeutic challenge. Results after coronary artery bypass surgery are suboptimal, whereas the use of bare metal stents is limited by high rates of restenosis. The introduction of DES prompted treatment of long diffuse disease with multiple overlapping stents.
METHODS: All consecutive patients with de novo diffuse LAD disease treated with more than 60-mm long DES from April 2002 to March 2004 were analyzed.
RESULTS: The study population consisted of 66 patients. Thirty-nine patients were treated with sirolimus-eluting stents (SES), average length 84 +/- 22 mm, and 27 patients with paclitaxel-eluting stents (PES), average length 74 +/- 14 mm. The number of stents implanted per patient was 2.8 +/- 0.7, whereas the mean total stent length for the LAD treatment was 80 +/- 20 mm. Angiographic as well as procedural success was achieved in 95% of cases. Eleven (16.6%) patients had in-hospital non-Q-wave myocardial infarction (five SES and six PES), and one patient developed intraprocedural stent thrombosis. All patients had clinical follow-up, and 52 patients (79%) had an angiographic follow-up at six months. Hierarchical major adverse cardiac event rate was 15% (7.5% for SES and 7.5% for PES). No patients died, one patient had non-Q-wave myocardial infarction (non-index vessel), and 10 patients (15%) underwent target vessel revascularization.
CONCLUSIONS: The implantation of multiple overlapping DES in patients with a diffusely diseased LAD is relatively safe and associated with good midterm clinical outcomes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15893168     DOI: 10.1016/j.jacc.2005.01.049

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  11 in total

1.  Interventional cardiology: does stent overlap make a difference to clinical outcome?

Authors:  Antonio Colombo; Rasha Al-Lamee
Journal:  Nat Rev Cardiol       Date:  2010-07       Impact factor: 32.419

2.  Drug deposition in coronary arteries with overlapping drug-eluting stents.

Authors:  Farhad Rikhtegar; Elazer R Edelman; Ufuk Olgac; Dimos Poulikakos; Vartan Kurtcuoglu
Journal:  J Control Release       Date:  2016-07-16       Impact factor: 9.776

3.  Utility of drug-eluting stents in complex lesions and high-risk patients.

Authors:  Eugenia Nikolsky; Gregg W Stone
Journal:  Curr Treat Options Cardiovasc Med       Date:  2007-02

4.  Impact of heterogeneous overlapping drug-eluting stents on the arterial responses of rabbit iliac arteries: a comparison with overlapping bare metal stents.

Authors:  Seung-Woon Rha; Kang-Yin Chen; Dong Joo Oh; Yong-Jian Li; Zhe Jin; Kanhaiya Lal Poddar; Sureshkumar Ramasamy; Yoshiyasu Minami; Amro Elnagar; Byoung Geol Choi; Sang Pyo Hong; Byoung Won Cheon; Sang Ki Moon; Sung Il Im; Sun Won Kim; Jin Oh Na; Cheol Ung Choi; Hong Euy Lim; Jin Won Kim; Eung Ju Kim; Seong Woo Han; Chang Gyu Park; Hong Seog Seo; Jung Ha Kim; Young Joon Hong; Myung Ho Jeong
Journal:  Korean Circ J       Date:  2012-06-28       Impact factor: 3.243

5.  Outcomes of stenting with overlapping drug-eluting stents versus overlapping drug-eluting and bare-metal stents for the treatment of diffuse coronary lesions.

Authors:  S E Kassaian; M Salarifar; M Raissi Dehkordi; M Alidoosti; E Nematipour; H R Poorhosseini; A M Hajizeinali; D Kazemisaleh; A Sharafi; M Mahmoodian; N Paydari; A V Farahani
Journal:  Cardiovasc J Afr       Date:  2010 Nov-Dec       Impact factor: 1.167

6.  Percutaneous coronary intervention using a full metal jacket with drug-eluting stents: major adverse cardiac events at one year.

Authors:  Rita Calé; Rui Campante Teles; Manuel Almeida; Ingrid do Rosário; Pedro Jerónimo Sousa; João Brito; Luís Raposo; Pedro de Araújo Gonçalves; Henrique Mesquita Gabriel; Miguel Mendes
Journal:  Arq Bras Cardiol       Date:  2013-07-02       Impact factor: 2.000

7.  Comparison of full lesion coverage versus spot drug-eluting stent implantation for coronary artery stenoses.

Authors:  Seunghwan Kim; Kyeong Ho Yun; Woong Chol Kang; Dong-Ho Shin; Jung-Sun Kim; Byeong-Keuk Kim; Young-Guk Ko; Donghoon Choi; Yangsoo Jang; Myeong-Ki Hong
Journal:  Yonsei Med J       Date:  2014-04-01       Impact factor: 2.759

8.  Risk-stratified cardiovascular screening including angiographic and procedural outcomes of percutaneous coronary interventions in renal transplant candidates.

Authors:  Julian König; Martin Möckel; Eda Mueller; Wolfgang Bocksch; Seema Baid-Agrawal; Nina Babel; Ralf Schindler; Petra Reinke; Peter Nickel
Journal:  J Transplant       Date:  2014-06-19

9.  Percutaneous coronary intervention in nonagenarians: pros and cons.

Authors:  Giuseppe Biondi Zoccai; Antonio Abbate; Fabrizio D'Ascenzo; Davide Presutti; Mariangela Peruzzi; Elena Cavarretta; Antonino G M Marullo; Marzia Lotrionte; Giacomo Frati
Journal:  J Geriatr Cardiol       Date:  2013-03       Impact factor: 3.327

10.  Clinical Efficacy and Safety of SeQuent Please Paclitaxel-Eluting Balloon in a Real-World Single-Center Registry of South-East Asian Patients.

Authors:  Hee Hwa Ho; Yau Wei Ooi; Kwok Kong Loh; Julian Tan; Than Htike Aung; Fahim Haider Jafary; Paul Jau Lueng Ong
Journal:  Int J Cardiol Heart Vessel       Date:  2013-11-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.